Combo Products Guidance Could Help Point Novel OTC Switches In Right Direction
This article was originally published in The Tan Sheet
Executive Summary
FDA delivers a draft GMPs guidance for combination products, providing details and examples on how the agency regulates drug delivery devices and other drug/device products. The document could be useful for firms interested in proposing novel Rx-to-OTC switches.
You may also be interested in...
FDA Draft Guidance Points Upward For OTC Wellness Device Development
The decision algorithm and flexible approach in a draft guidance on general wellness products will support innovative mobile health development, an industry advocate says. FDA does not intend to review low-risk OTC products, such as exercise equipment, that claim to support various facets of patients' wellness.
FDA Draft Guidance Points Upward For OTC Wellness Device Development
The decision algorithm and flexible approach in a draft guidance on general wellness products will support innovative mobile health development, an industry advocate says. FDA does not intend to review low-risk OTC products, such as exercise equipment, that claim to support various facets of patients' wellness.
Industry Seeks More Clarity Following Combo Product GMP Final Rule
FDA’s final regulation outlines which manufacturing system requirements apply to products that have drug, device and/or biologic components. An industry coalition says key details need to be filled in by FDA with guidance.